SEC Form 4 · accession 0001628280-26-040830
STERIS plc · STE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard C Breeden
Director
Period of report
Jun 2, 2026
Accepted (ET)
Jun 4, 2026 · 4:31 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001757898
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jun 2, 2026 | M | 3,781 | $71.40 | A | 40,445 | D | |
| Ordinary SharesF1 | Jun 2, 2026 | S | 1,481 | $209.51 | D | 38,964 | D | |
| Ordinary SharesF2,F3 | holding | — | — | — | 27,242 | I | See Footnotes Below |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F4 | $71.40 | Jun 2, 2026 | M | 3,781 | D | — | Aug 10, 2026 | Ordinary Shares | 3,781 | 0 | D |
Explanation of responses
- F1Price reflects a weighted average sale price for multiple transactions ranging from $209.50 to $209.53 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F2Richard C. Breeden is the managing member of Breeden Capital Partners LLC, and managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC (the "General Partner") is in turn the general partner of Breeden Partners L.P. (the "Fund").
- F3Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares. Mr. Breeden disclaims beneficial ownership over 1,358 of these shares held by Breeden Partnership LLP.
- F4This option to purchase 3,781 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 3,781 ordinary shares for $71.40 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option.